DGAP-News: MOLOGEN AG: Active principle for cancer medication MGN1703 proven
(firmenpresse) - MOLOGEN AG / Key word(s): Miscellaneous
30.09.2010 15:49
---------------------------------------------------------------------------
MOLOGEN AG has taken a significant step forward in the development of its
cancer medication. A further evaluation sequence of data from the company's
clinical study shows by means of biomarkers the potential of the active
ingredient in the therapy of cancer.
Berlin, September 30, 2010 - MOLOGEN AG has evaluated a further sequence of
clinical data from the completed phase Ib trial with the cancer medication
MGN1703. The analysis of biomarkers of the patients' immune system
exemplarily shows the effect of MGN1703 on the immune system of cancer
patients. It was shown that the immune system of the patients is broadly
activated and in a manner that is necessary for a successful battle with
tumor diseases.
The exemplary data achieved from the clinical trial confirms the results
shown in preclinical trials and in vitro studies.
Prof. Dr. Burghardt Wittig, Chairman of the scientific advisory board of
MOLOGEN AG, has commented: 'The evidence of activation markers for all
cellular check points of the immune system can now be shown for the first
time in patients with heavily damaged immune systems. The scientific
concept of dSLIM(R), the molecule which is behind MGN1703, has been
confirmed by this once again.'
The data was seen as very positive, in light of the health condition of the
patients who were being treated in the already completed clinical study of
phase Ib. The immune system of the patients had been severely damaged from
several month-long pretreatments with various types of chemotherapy, and as
such, a successful evaluation of the biomarkers can not be assumed per se.
Dr. Matthias Schroff, CEO of MOLOGEN AG, has responded very optimistically
to these interim results: 'We have additional data on hand which proves the
comprehensive effect of MGN1703 on the immune system. My confidence -
especially as a scientist - is greater than ever that our current Phase
II/III study will show the efficacy of the medication. We have been able to
establish a link in the chain of evidence with this which should be
meaningful not only for our entire product pipeline, but also for
investors.'
The cancer medication MGN1703 is currently being investigated in the course
of a phase II/III clinical study that is relevant for the approval in the
treatment of metastasized colorectal cancer. The goal of the study is to
significantly prevent the progression of the cancer significantly longer
than has been possible with the treatment methods up to now. The study is
currently being conducted at various study centers in Germany and Austria.
First results shall be available after an interim evaluation in the first
half of 2011.
About MOLOGEN AG
Die MOLOGEN AG, a German biopharmaceutical company with headquarters in
Berlin specializes in the research and development of innovative
medications on the basis of DNA structures. The activities focus on
numerous product developments which are relevant to the immune system; on
the one hand vaccines against infectious diseases and on the other hand
cancer medications. MOLOGEN AG is globally one of the few biotechnology
companies with well tolerated DNA-based cancer treatment in the clinical
development phase.
The stocks of MOLOGEN AG are listed in the Prime Standard of the German
stock exchange (ISIN DE0006637200).
MOLOGENAG
Jörg PetraßCFO
Phone: +49 - 30 - 84 17 88 - 13
Fax: +49 - 30 - 84 17 88 - 50
investor(at)mologen.com
Prof. Peter W. Hübner
Director of Corporate Communications
Phone: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
huebner(at)mologen.com
Kirchhoff Consult AG
Janina Wismar
Phone: +49 - 40 - 60 91 86 - 50
Fax: +49 - 40 - 60 91 86 - 16
janina.wismar(at)kirchhoff.de
30.09.2010 15:49 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Deutschland
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: info(at)mologen.com
Internet: www.mologen.com
ISIN: DE0006637200
WKN: 663720
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Hamburg, München, Düsseldorf, Berlin, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Datum: 30.09.2010 - 15:49 Uhr
Sprache: Deutsch
News-ID 32288
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 266 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: MOLOGEN AG: Active principle for cancer medication MGN1703 proven"
steht unter der journalistisch-redaktionellen Verantwortung von
MOLOGEN AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
